{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:44:46Z","timestamp":1782708286605,"version":"3.54.5"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,7,20]]},"DOI":"10.1038\/s41416-026-03388-z","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:55:52Z","timestamp":1776884152000},"page":"303-315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer"],"prefix":"10.1038","volume":"135","author":[{"given":"Suhail","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Butle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Karn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roma","family":"Sunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhargavi","family":"Bawaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Parab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vividh","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-8757","authenticated-orcid":false,"given":"Rohan","family":"Chaubal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanuja","family":"Shet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6742-6378","authenticated-orcid":false,"given":"Sudeep","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1119-4774","authenticated-orcid":false,"given":"Amit","family":"Dutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"3388_CR1","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687\u2013717.","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"3388_CR2","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341\u201352.","DOI":"10.1016\/S0140-6736(15)61074-1"},{"key":"3388_CR3","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451\u201367.","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"3388_CR4","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/S0960-9776(19)31118-X","volume":"48","author":"JT Lei","year":"2019","unstructured":"Lei JT, Anurag M, Haricharan S, Gou X, Ellis MJ. Endocrine therapy resistance: new insights. Breast. 2019;48:S26\u201330.","journal-title":"Breast"},{"key":"3388_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ccell.2017.07.005","volume":"32","author":"LR Yates","year":"2017","unstructured":"Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Martincorena I, et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell. 2017;32:169\u2013184.e167.","journal-title":"Cancer Cell"},{"key":"3388_CR6","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/ng.2823","volume":"45","author":"DR Robinson","year":"2013","unstructured":"Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45:1446\u201351.","journal-title":"Nat Genet"},{"key":"3388_CR7","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1093\/annonc\/mdw286","volume":"27","author":"D Fumagalli","year":"2016","unstructured":"Fumagalli D, Wilson TR, Salgado R, Lu X, Yu J, O\u2019Brien C, et al. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. Ann Oncol. 2016;27:1860\u20136.","journal-title":"Ann Oncol"},{"key":"3388_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s42003-025-07606-x","volume":"8","author":"A Ghosh","year":"2025","unstructured":"Ghosh A, Chaubal R, Das C, Parab P, Das S, Maitra A, et al. Genomic hallmarks of endocrine therapy resistance in ER\/PR+HER2- breast tumours. Commun Biol. 2025;8:207.","journal-title":"Commun Biol"},{"key":"3388_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8758","volume":"6","author":"A Stone","year":"2015","unstructured":"Stone A, Zotenko E, Locke WJ, Korbie D, Millar EK, Pidsley R, et al. DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. Nat Commun. 2015;6:7758.","journal-title":"Nat Commun"},{"key":"3388_CR10","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41588-019-0507-7","volume":"51","author":"L Angus","year":"2019","unstructured":"Angus L, Smid M, Wilting SM, van Riet J, Van Hoeck A, Nguyen L, et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat Genet. 2019;51:1450\u20138.","journal-title":"Nat Genet"},{"key":"3388_CR11","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/ng.2822","volume":"45","author":"W Toy","year":"2013","unstructured":"Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45:1439\u201345.","journal-title":"Nat Genet"},{"key":"3388_CR12","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/annonc\/mdy025","volume":"29","author":"RJ Hartmaier","year":"2018","unstructured":"Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann Oncol. 2018;29:872\u201380.","journal-title":"Ann Oncol"},{"key":"3388_CR13","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","volume":"70","author":"N Turner","year":"2010","unstructured":"Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70:2085\u201394.","journal-title":"Cancer Res"},{"key":"3388_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41588-018-0287-5","volume":"51","author":"U Nayar","year":"2019","unstructured":"Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, et al. Acquired HER2 mutations in ER(+) metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nat Genet. 2019;51:207\u201316.","journal-title":"Nat Genet"},{"key":"3388_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","volume":"10","author":"C Costa","year":"2020","unstructured":"Costa C, Wang Y, Ly A, Hosono Y, Murchie E, Walmsley CS, et al. PTEN loss mediates clinical cross-resistance to CDK4\/6 and PI3Kalpha inhibitors in breast cancer. Cancer Discov. 2020;10:72\u201385.","journal-title":"Cancer Discov"},{"key":"3388_CR16","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/1078-0432.CCR-18-4044","volume":"26","author":"A Pearson","year":"2020","unstructured":"Pearson A, Proszek P, Pascual J, Fribbens C, Shamsher MK, Kingston B, et al. Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance. Clin Cancer Res. 2020;26:608\u201322.","journal-title":"Clin Cancer Res"},{"key":"3388_CR17","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/j.clbc.2016.05.014","volume":"16","author":"S Shiino","year":"2016","unstructured":"Shiino S, Kinoshita T, Yoshida M, Jimbo K, Asaga S, Takayama S, et al. Prognostic impact of discordance in hormone receptor status between primary and recurrent sites in patients with recurrent breast cancer. Clin Breast Cancer. 2016;16:e133\u201340.","journal-title":"Clin Breast Cancer"},{"key":"3388_CR18","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1200\/JCO.2005.01.172","volume":"23","author":"MC Gutierrez","year":"2005","unstructured":"Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005;23:2469\u201376.","journal-title":"J Clin Oncol"},{"key":"3388_CR19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ccell.2020.08.003","volume":"38","author":"A Arruabarrena-Aristorena","year":"2020","unstructured":"Arruabarrena-Aristorena A, Maag JLV, Kittane S, Cai Y, Karthaus WR, Ladewig E, et al. FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer. Cancer Cell. 2020;38:534\u2013550.e539.","journal-title":"Cancer Cell"},{"key":"3388_CR20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41588-019-0554-0","volume":"52","author":"G Xu","year":"2020","unstructured":"Xu G, Chhangawala S, Cocco E, Razavi P, Cai Y, Otto JE, et al. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nat Genet. 2020;52:198\u2013207.","journal-title":"Nat Genet"},{"key":"3388_CR21","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.18.00925","volume":"37","author":"NC Turner","year":"2019","unstructured":"Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2019;37:1169\u201378.","journal-title":"J Clin Oncol"},{"key":"3388_CR22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell. 2020;37:496\u2013513.","journal-title":"Cancer Cell"},{"key":"3388_CR23","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370.","DOI":"10.1038\/nature11412"},{"key":"3388_CR24","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-024-08167-5","volume":"636","author":"J Jee","year":"2024","unstructured":"Jee J, Fong C, Pichotta K, Tran TN, Luthra A, Waters M, et al. Automated real-world data integration improves cancer outcome prediction. Nature. 2024;636:728\u201336.","journal-title":"Nature"},{"key":"3388_CR25","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","volume":"569","author":"F Bertucci","year":"2019","unstructured":"Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, et al. Genomic characterization of metastatic breast cancers. Nature. 2019;569:560\u20134.","journal-title":"Nature"},{"key":"3388_CR26","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41588-019-0507-7","volume":"51","author":"L Angus","year":"2019","unstructured":"Angus L, Smid M, Wilting SM, van Riet J, Van Hoeck A, Nguyen L, et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nature Genetics. 2019;51:1450\u20138.","journal-title":"Nature Genetics"},{"key":"3388_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34:427\u2013438.e426.","journal-title":"Cancer Cell"},{"key":"3388_CR28","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214\u20138.","journal-title":"Nature"},{"key":"3388_CR29","doi-asserted-by":"publisher","first-page":"68012","DOI":"10.18632\/oncotarget.12010","volume":"7","author":"L Malorni","year":"2016","unstructured":"Malorni L, Piazza S, Ciani Y, Guarducci C, Bonechi M, Biagioni C, et al. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget. 2016;7:68012\u201322.","journal-title":"Oncotarget"},{"key":"3388_CR30","doi-asserted-by":"crossref","unstructured":"Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, et al. Genomic profi ling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2017;9:eaai7993.","DOI":"10.1126\/scitranslmed.aai7993"},{"key":"3388_CR31","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1002\/ijc.25297","volume":"127","author":"M Stendahl","year":"2010","unstructured":"Stendahl M, Nilsson S, Wigerup C, Jirstrom K, Jonsson PE, Stal O, et al. p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients. Int J Cancer. 2010;127:2851\u20138.","journal-title":"Int J Cancer"},{"key":"3388_CR32","doi-asserted-by":"crossref","unstructured":"Kim HS, Noh YK, Min KW, Kim DH. Low CDKN1B expression associated with reduced CD8+ T lymphocytes predicts poor outcome in breast cancer in a machine learning analysis. J Pers Med. 2023;14:30.","DOI":"10.3390\/jpm14010030"},{"key":"3388_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00734-3","volume":"7","author":"S Berton","year":"2017","unstructured":"Berton S, Cusan M, Segatto I, Citron F, D\u2019Andrea S, Benevol S, et al. Loss of p27(kip1) increases genomic instability and induces radio-resistance in luminal breast cancer cells. Sci Rep. 2017;7:595.","journal-title":"Sci Rep"},{"key":"3388_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1530\/ERC-10-0262","volume":"18","author":"C Thangavel","year":"2011","unstructured":"Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocrine Related Cancer. 2011;18:333\u201345.","journal-title":"Endocrine Related Cancer"},{"key":"3388_CR35","doi-asserted-by":"crossref","unstructured":"Guiley KZ, Stevenson JW, Lou K, Barkovich KJ, Kumarasamy V, Wijeratne TU, et al. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science. 2019;366:eaaw2106.","DOI":"10.1126\/science.aaw2106"},{"key":"3388_CR36","doi-asserted-by":"crossref","unstructured":"Rampioni Vinciguerra GL, Dall\u2019Acqua A, Segatto I, Mattevi MC, Russo F, et al. p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer. Cell Death Dis. 2021;12:951.","DOI":"10.1038\/s41419-021-04241-2"},{"key":"3388_CR37","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature. 2012;486:346\u201352.","journal-title":"Nature"},{"key":"3388_CR38","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1200\/JCO.2003.02.021","volume":"21","author":"G Pohl","year":"2003","unstructured":"Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, et al. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol. 2003;21:3594\u2013600.","journal-title":"J Clin Oncol"},{"key":"3388_CR39","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1158\/1078-0432.CCR-09-0728","volume":"15","author":"M Filipits","year":"2009","unstructured":"Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, et al. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Clin Cancer Res. 2009;15:5888\u201394.","journal-title":"Clin Cancer Res"},{"key":"3388_CR40","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1158\/0008-5472.CAN-20-2275","volume":"81","author":"V Kumarasamy","year":"2021","unstructured":"Kumarasamy V, Vail P, Nambiar R, Witkiewicz AK, Knudsen ES. Functional determinants of cell cycle plasticity and sensitivity to CDK4\/6 inhibition. Cancer Res. 2021;81:1347\u201360.","journal-title":"Cancer Res"},{"key":"3388_CR41","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1158\/1541-7786.MCR-18-0188","volume":"17","author":"SRS Gottesman","year":"2019","unstructured":"Gottesman SRS, Somma J, Tsiperson V, Dresner L, Govindarajulu U, Patel P, et al. Tyrosine phosphorylation of p27Kip1 correlates with Palbociclib responsiveness in breast cancer tumor cells grown in explant culture. Mol Cancer Res. 2019;17:669\u201375.","journal-title":"Mol Cancer Res"},{"key":"3388_CR42","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1158\/1541-7786.MCR-20-0623","volume":"19","author":"SP Gao","year":"2021","unstructured":"Gao SP, Kiliti AJ, Zhang K, Vasani N, Mao N, Jordan E, et al. AKT1 E17K inhibits cancer cell migration by abrogating beta-catenin signaling. Mol Cancer Res. 2021;19:573\u201384.","journal-title":"Mol Cancer Res"},{"key":"3388_CR43","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1158\/2159-8290.CD-19-1209","volume":"10","author":"LM Smyth","year":"2020","unstructured":"Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, et al. Characteristics and outcome of AKT1E17K-mutant breast cancer defined through AACR project GENIE, a clinicogenomic registry. Cancer Discovery. 2020;10:526\u201335.","journal-title":"Cancer Discovery"},{"key":"3388_CR44","doi-asserted-by":"crossref","unstructured":"Chaubal R, Talker E, Chitra J, Kadam R, Gardi N, Ursekar R et al. Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer. Breast Cancer Res Treat. 2025;213:247\u201359.","DOI":"10.1007\/s10549-025-07759-7"},{"key":"3388_CR45","doi-asserted-by":"publisher","first-page":"e0231999","DOI":"10.1371\/journal.pone.0231999","volume":"15","author":"J Rinaldi","year":"2020","unstructured":"Rinaldi J, Sokol ES, Hartmaier RJ, Trabucco SE, Frampton GM, Goldberg ME, et al. The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors. PLoS ONE. 2020;15:e0231999.","journal-title":"PLoS ONE"},{"key":"3388_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103542","volume":"71","author":"B Chen","year":"2021","unstructured":"Chen B, Zhang G, Lai J, Xiao W, Li X, Li C, et al. Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours. EBioMedicine. 2021;71:103542.","journal-title":"EBioMedicine"},{"key":"3388_CR47","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00647","volume":"8","author":"M Hattori","year":"2024","unstructured":"Hattori M, Serelli-Lee V, Naito Y, Yamanaka T, Yasojima H, Nakamura R, et al. Genomic landscape of circulating tumor DNA in patients with hormone receptor-positive\/human epidermal growth factor receptor-2-negative metastatic breast cancer treated with abemaciclib: data from the Scrum-Japan Cancer Genome Screening Project. JCO Precis Oncol. 2024;8:e2300647.","journal-title":"JCO Precis Oncol"},{"key":"3388_CR48","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"P Rastogi","year":"2024","unstructured":"Rastogi P, O\u2019Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarche overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42:987\u201393.","journal-title":"J Clin Oncol"},{"key":"3388_CR49","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390:1080\u201391.","journal-title":"N Engl J Med"},{"key":"3388_CR50","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","volume":"8","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The genetic landscape and clonal evolution of breast cancer resistance to Palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discovery. 2018;8:1390\u2013403.","journal-title":"Cancer Discovery"},{"key":"3388_CR51","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 2020;10:1174\u201393.","journal-title":"Cancer Discov"},{"key":"3388_CR52","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1158\/1078-0432.CCR-22-2177","volume":"29","author":"AA Davis","year":"2023","unstructured":"Davis AA, Luo J, Zheng T, Dai C, Dong X, Tan L, et al. Genomic complexity predicts resistance to endocrine therapy and CDK4\/6 inhibition in hormone receptor-positive (HR+)\/HER2-negative metastatic breast cancer. Clin Cancer Res. 2023;29:1719\u201329.","journal-title":"Clin Cancer Res"},{"key":"3388_CR53","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10549-024-07415-6","volume":"208","author":"G Kimmick","year":"2024","unstructured":"Kimmick G, Pilehvari A, You W, Bonilla G, Anderson R. First- vs second-line CDK 4\/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting. Breast Cancer Res Treat. 2024;208:263\u201373.","journal-title":"Breast Cancer Res Treat"},{"key":"3388_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2021.104718","volume":"123","author":"MN Said","year":"2021","unstructured":"Said MN, Muawia S, Helal A, Fawzy A, Allam RM, Shafik NF. Regulation of CDK inhibitor p27 by microRNA 222 in breast cancer patients. Exp Mol Pathol. 2021;123:104718.","journal-title":"Exp Mol Pathol"},{"key":"3388_CR55","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.1073\/pnas.1817415116","volume":"116","author":"H Yoon","year":"2019","unstructured":"Yoon H, Kim M, Jang K, Shin M, Besser A, Xiao X, et al. p27 transcriptionally coregulates cJun to drive programs of tumor progression. Proc Natl Acad Sci USA. 2019;116:7005\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3388_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.molcel.2004.09.029","volume":"16","author":"P Ji","year":"2004","unstructured":"Ji P, Jiang H, Rekhtman K, Bloom J, Ichetovkin M, Pagano M, et al. An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. Mol Cell. 2004;16:47\u201358.","journal-title":"Mol Cell"},{"key":"3388_CR57","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1073\/pnas.96.5.1858","volume":"96","author":"Z Nawaz","year":"1999","unstructured":"Nawaz Z, Lonard DM, Dennis AP, Smith CL, O\u2019Malley BW. Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA. 1999;96:1858\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3388_CR58","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1097-2765(00)80259-2","volume":"5","author":"DM Lonard","year":"2000","unstructured":"Lonard DM, Nawaz Z, Smith CL, O\u2019Malley BW. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell. 2000;5:939\u201348.","journal-title":"Mol Cell"},{"key":"3388_CR59","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1038\/onc.2013.197","volume":"33","author":"W Zhou","year":"2014","unstructured":"Zhou W, Srinivasan S, Nawaz Z, Slingerland JM. ERalpha, SKP2 and E2F-1 form a feed forward loop driving late ERalpha targets and G1 cell cycle progression. Oncogene. 2014;33:2341\u201353.","journal-title":"Oncogene"},{"key":"3388_CR60","doi-asserted-by":"publisher","first-page":"875","DOI":"10.18632\/oncotarget.1036","volume":"4","author":"I Caligiuri","year":"2013","unstructured":"Caligiuri I, Toffoli G, Giordano A, Rizzolio F. pRb controls estrogen receptor alpha protein stability and activity. Oncotarget. 2013;4:875\u201383.","journal-title":"Oncotarget"},{"key":"3388_CR61","doi-asserted-by":"publisher","first-page":"29897","DOI":"10.1074\/jbc.M804612200","volume":"283","author":"TE Miller","year":"2008","unstructured":"Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, et al. MicroRNA-221\/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008;283:29897\u2013903.","journal-title":"J Biol Chem"},{"key":"3388_CR62","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/jnci\/djq102","volume":"102","author":"G Di Leva","year":"2010","unstructured":"Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, et al. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst. 2010;102:706\u201321.","journal-title":"J Natl Cancer Inst"},{"key":"3388_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7.","journal-title":"BMC Bioinform"},{"key":"3388_CR64","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/ng.3073","volume":"46","author":"ML Gatza","year":"2014","unstructured":"Gatza ML, Silva GO, Parker JS, Fan C, Perou CM. An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nature Genetics. 2014;46:1051\u20139.","journal-title":"Nature Genetics"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03388-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03388-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03388-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:02:52Z","timestamp":1782705772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03388-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7,20]]}},"alternative-id":["3388"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03388-z","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Institutional Ethics Committee III and registered with CTRI (CTRI\/2017\/11\/010553). All freshly preserved tumor tissues were bio-banked patients provided their written informed consent under IEC protocol 239. Since no additional procedures was required to be performed, all retrospectively collected FFPE blocks archived by our pathology department as part of standard of care were taken for this study post a waiver of patient consent as approved by our IEC under study protocol 239. All in vivo experiments were conducted with approval from the Institutional Animal Ethics Committee (IAEC), TMC-ACTREC Approval No. (12\/2022). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}